Riken Corporation

Sysmex Corporation

The Jikei University

Soichi Kojima

Naoshi Dohmae

Takehisa Matsumoto

Wakako Kondo

Takashi Saito

Mikako Shirouzu

Tomokazu Matsuura

Daisuke Takaya

Toshitada Takemori

Kozo Suto

Ikuyo Inoue

Mitsuko Hara

Takahiro Masaki

Chiemi Tsumagari

Masahiro Miura

Disclosed is an isolated monoclonal antibody against a human Transforming Growth Factor-&#x3b2; (TGF-&#x3b2;) Latency Associated Protein (LAP) degradate, the isolated monoclonal antibody being capable of recognizing an integrin binding site in the human TGF-&#x3b2; LAP degradate.

Antibody against human TGF-&#x3b2; LAP degradate, and use thereof

An object is to provide a compound capable of inhibiting activation of TGF-&#x3b2; receptors due to HCV, and a screening method for the compound. It has been found that a HCV-derived NS3 protease binds to type I TGF-&#x3b2; receptor, and this binding results in activation of TGF-&#x3b2; receptors. Moreover, binding sites between the NS3 protease and type I TGF-&#x3b2; receptor were identified, and it has been found that antibodies recognizing these binding sites inhibit activation of TGF-&#x3b2; receptors due to NS3 protease. Furthermore, it has been also found that screening for a compound capable of inhibiting activation of TGF-&#x3b2; receptors can be performed by using the inhibition of the binding between NS3 protease and type I TGF-&#x3b2; receptor or the like as an index.

Compounds having activity of suppressing activation of TGF-&#x3b2; receptor, method for screening of the compounds, and composition for preventing or treating disease caused by hepatitis C virus

It is an object of the present invention to provide antibodies capable of detecting an active TGF-&#x3b2; generation reaction that is specific to pathogenesis, tissues, or isoforms. The present invention provides antibodies against an LAP fragment (or latent TGF-&#x3b2;) generated as a result of generation of active form of human TGF-&#x3b2;1, human TGF-&#x3b2;2 and human TGF-&#x3b2;3. The antibodies are able to specifically recognize respective cutting edges within protease cleavage sites existing in the region from the amino acid residue glycine at position 51 to the amino acid residue arginine at position 110 of human TGF-&#x3b2;1, and corresponding regions of human TGF-&#x3b2;2 and human TGF-&#x3b2;3.

Antibodies that recognize cutting edge within the TGF-&#x3b2; activation controlling region

It is an object of the present invention to provide antibodies capable of detecting an active TGF-&#x3b2; generation reaction that is specific to pathogenesis, tissues, or isoforms. The present invention provides antibodies against an LAP fragment (or latent TGF-&#x3b2;) generated as a result of generation of active form of human TGF-&#x3b2;1, human TGOF-&#x3b2;2 and human TGF-&#x3b2;3. The antibodies are able to specifically recognize respective cutting edges within protease cleavage sites existing in the region from the amino acid residue glycine at position 51 to the amino acid residue arginine at position 110 of human TGF-&#x3b2;1, and corresponding regions of human TGF-&#x3b2;2 and human TGF-&#x3b2;3.

Methods of use of antibodies which recognize a protease cleavage site of an LAP fragment of TGF-&#x3b2;

Growing community of inventors

Wako, Japan

Soichi Kojima